QUATRx Pharmaceuticals

QUATRx is building a portfolio of novel drug opportunities in a variety of therapeutic areas through in-licensing. Through the application of novel strategies, we plan to develop these rapidly, usually through to the end of Phase 2. This will add substantial value to the compounds prior to out-licensing to the final marketing partners, enabling QUATRx and its investors to realize highly attractive rates of return on the development investment and providing physicians access to innovative new therapies to treat diseases inadequately addressed by existing therapies. The initial focus of the company is drugs selectively targeting nuclear receptors. Nuclear receptors are proteins in the cell nucleus that act as receivers for a number of key hormones and govern a wide range of essential metabolic and developmental processes in the body. Through the understanding of nuclear receptors in drug design, new tissue selective drugs with enhanced benefits and fewer side effects can be developed, providing exciting opportunities for QUATRx.

Other therapeutic areas, including endocrine and metabolic diseases, cardiovascular disease and dermatology are also of particular interest to the Company, where clinical end points are well defined and development to the end of Phase 2 can be accomplished in a relatively short timescale.

Contact Details: 5430 Data Court, Suite 300 Ann Arbor MI 48108 United States of America Tel: 734 - 913-9900 Fax: 734 - 913-0743 Email: cnicholas@quatrx.com WWW: www.quatrx.com/

Loading...

BioNews Results for QUATRx Pharmaceuticals:
PharmaVigilant Demystifies Clinical Trial Process Costs and Improves Access to Data by Offering Sponsors Compl	Genetic Engineering News:  Nov 3 2009 2:18PM Matching: quatrx pharmaceuticals
Hercules Technology Growth Capital Announces Three Portfolio Companies That Reached Multi-Million Dollar Miles	Pharmacy Choice:  Oct 21 2009 9:22AM Matching: quatrx pharmaceuticals
Hercules Technology Growth Capital Announces Three Portfolio Companies That Reached Multi-Million Dollar Milestones	FinanzNachrichten.de:  Oct 20 2009 6:59PM Matching: quatrx pharmaceuticals
Hercules Technology Growth Capital Announces Three Portfolio Companies That Reached Multi-Million Dollar Milestones	FinanzNachrichten.de:  Oct 20 2009 6:58PM Matching: quatrx pharmaceuticals
Hercules Technology Growth Capital Announces Three Portfolio Companies That Reached Multi-Million Dollar Miles	Street Insider:  Oct 20 2009 7:11PM Matching: quatrx pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more QUATRx Pharmaceuticals news.

QUATRx Pharmaceuticals Clinical Trials:
Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 359 times since April 2007, the link to the organisation's website has been followed 69 times

Search for more companies in Ann Arbor

Search for more companies in MI

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for QUATRx Pharmaceuticals